详文均见于”最近进展”（除非另有说明）; 同一文章可能见于本节内不同分类
Full articles can be found under “Recent Progress” unless specified; same reports may be classified under different categories in this section
乳腺癌 Breast cancer
3/1/2026 晚期乳腺癌一线与二线 CDK4/6 抑制剂对总生存期无差别 First-line vs second-line CDK4/6 inhibitor does not impact overall survival in advanced breast cancer: SONIA trial
2/21/2026 术前放疗或可改善乳腺癌的抗肿瘤免疫反应 Preoperative radiation may improve antitumor immune response in breast cancer
2/15/2026 Olaparib monotherapy for metastatic breast cancer with germline mutations in PALB2 or somatic mutations in BRCA1/BRCA2: TBCRC 048 trial
1/4/2026 比较 giredestrant 与标准内分泌疗法作为ER阳性/HER2 阴性早期乳腺癌辅助治疗 Adjuvant therapy using giredestrant vs standard-of-care for ER-positive, HER2-negative early breast cancer: lidERA trial
肺癌 Lung cancer
2/22/2026 FDA 已批准 amivantamab-vmjw (皮下注射)联合 lazertinib作为一线疗法用于晚期 EGFR突变型非小细胞肺癌 The FDA has approved (subcutaneous) amivantamab-vmjw in combination with lazertinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer
2/1/2026 Imneskibart 联合白介素-2在黑色素瘤和非小细胞肺癌中展现抗肿瘤活性 Imneskibart in combination with interleukin-2 demonstrates antitumor activity in melanoma and non-small cell lung cancer
1/25/2026 FDA批准Sevabertinib用于非鳞状非小细胞肺癌 FDA approves Sevabertinib for non-squamous non-small cell lung cancer with HER2 TKD activating mutations
胃食管癌 Gastro-esophageal cancer
2/7/2026 Zanidatamab 联合化疗±tislelizumab 一线治疗HER2阳性晚期胃食管腺癌 Zanidatamab + chemotherapy ± tislelizumab for first-line HER2-positive locally advanced gastroesophageal adenocarcinoma: HERIZON-GEA-01
1/18/2026 Zanidatamab联合化疗一线治疗HER2阳性不可切除或转移性胃食管腺癌 Zanidatamab + chemotherapy ± for first-line HER2+ unresectable, or metastatic gastroesophageal adenocarcinoma: HERIZON-GEA-01
胰腺癌 Pancreatic cancer
3/14/2026 一种诊断治疗晚期胰腺导管腺癌的新型 KRAS G12D 抑制剂 A novel KRAS G12D inhibitor for advanced pancreatic ductal adenocarcinoma
1/31/2026 改进用于早期检测胰腺导管腺癌的血浆标志物 Improving a plasma biomarker panel for early detection of pancreatic ductal adenocarcinoma
1/17/2026 术前mFOLFIRINOX对比PAXG治疗可切除胰腺导管腺癌 Preoperative mFOLFIRINOX versus PAXG for resectable pancreatic ductal adenocarcinoma: PACT-21 CASSANDRA
尿路上皮癌 Urothelial cancer
1/24/2026 首创口服小分子PPARγ抑制剂治疗晚期尿路上皮癌 I 期试验 A phase I trial of first-in-class oral small molecule PPARγ inhibitor for the treatment of advanced urothelial carcinoma
膀胱癌 Bladder cancer
3/8/2026 ctDNA 指导肌层浸润性膀胱癌的疗效适应性膀胱保留治疗 ctDNA to guide response-adapted bladder preservation in muscle invasive bladder cancer: RETAIN trials
肾细胞癌 Renal cell carcinoma
3/15/2026 消融术与手术治疗T1a期肾细胞癌的长期疗效相当 Ablation and surgery for T1a renal cell carcinoma demonstrate comparable long-term outcomes: A Danish Nationwide Registry Study
卵巢癌 Ovarian cancer
2/8/2026 新型 CDK2抑制剂 INCB123667 用于铂类耐药性卵巢癌 A novel CDK2 inhibitor INCB123667 for platinum-resistant ovarian cancer
1/3/2026 Botensilimab 联合巴斯蒂利单抗联合 balstilimab 治疗难治性卵巢癌患者 Botensilimab plus balstilimab for refractory ovarian cancer
宫颈癌 Cervical cancer
3/7/2026 最新进展 Recent Progress–>Cadonilimab 治疗复发性宫颈癌 Bispecific cadonilimab in recurrent cervical cancer
黑色素瘤 Melanoma
2/1/2026 Imneskibart 联合白介素-2在黑色素瘤和非小细胞肺癌中展现抗肿瘤活性 Imneskibart in combination with interleukin-2 demonstrates antitumor activity in melanoma and non-small cell lung cancer
脑瘤/ 胶质母细胞瘤 Brain tumor/glioblastoma
2/14/2026 溶瘤病毒激活免疫系统对抗胶质母细胞瘤 Oncolytic viruses activate the immune system to treat glioblastoma
肿瘤生物学和治疗/诊断新进展 Tumor biology & New treatment/diagnosis progress
2/1/2026 Imneskibart 联合白介素-2在黑色素瘤和非小细胞肺癌中展现抗肿瘤活性 Imneskibart in combination with interleukin-2 demonstrates antitumor activity in melanoma and non-small cell lung cancer
流行病学 Epidemiology
2/28/2026 微塑料与前列腺癌 Microplastics and prostate cancer
1/11/2026 食品添加剂防腐剂摄入量与癌症发病率 Intake of food additive preservatives and incidence of cancer
1/10/2026 IgG4 相关疾病患者癌症风险增加 Increased cancer risk in patients with IgG4-related disease in South Korea